U.S. Markets open in 9 hrs 1 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
87.75-0.63 (-0.71%)
At close: 5:35PM CEST
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
Previous Close88.38
Open88.01
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range87.36 - 88.31
52 Week Range62.50 - 92.97
Volume2,180,590
Avg. Volume2,327,189
Market Cap110.45B
BetaN/A
PE Ratio (TTM)24.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters6 hours ago

    Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

    The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. The drug, sarilumab, which will be sold under the brand name Kevzara, will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses, which the companies said was about 30 percent lower than the list price for the two most widely used rival medicines in the highly competitive space. The approval marks a second major regulatory victory for the two companies in recent weeks after their potential blockbuster treatment for severe atopic dermatitis, Dupixent, won U.S. approval in late March.

  • Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
    Zacks8 hours ago

    Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

    Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

  • Benzinga10 hours ago

    Regeneron And Sanofi Have A Near-Term FDA Catalyst

    At the end of April, biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced that the FDA had accepted the resubmission of its Biologics License Application (BLA) for a drug called Kevzara. ...